An integrated disease/pharmacokinetic/pharmacodynamic model suggests improved interleukin-21 regimens validated prospectively for mouse solid cancers. - Elishmereni M; Kheifetz Y; Søndergaard H; Overgaard RV; Agur Z (PLoS computational biology, 2011)